It was evaluated first in the human phase I trial of adult patients with advanced BRAFV600-mutated solid tumors, including those with an active brain metastasis or primary CNS cancer, regardless of prior BRAF inhibitor use [119]. The gene discussed is BRAF; the disease is central nervous system cancer.